Save time and jump to the most important pieces.
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
HC Wainwright & Co. reiterated coverage of Protalix BioTherapeutics with a rating of Buy and set a new price target of $7.00 from $11.00 previously
4/A - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)
CARMIEL, Israel, May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place on Tuesday, May 20, 2025 at the Nasdaq headquarters in New York City, New York. Eyal Rubin, the Company's Sr. Vice President and Chief Financial Officer, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Investors
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update. "We had another solid quarter, with an increase in revenues from selling goods compared to the prior year quarter," said Dror Bashan, Protalix's President and Chief Executive Officer. "Given the promising resul
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date:
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update. "We had another solid quarter, with an increase in revenues from selling goods compared to the prior year quarter," said Dror Bashan, Protalix's President and Chief Executive Officer. "Given the promising resul
Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date:
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update. "2024 was a record year in revenues from selling goods for Protalix, as we experienced increases in all three of our revenue streams, Chiesi, Pfizer and Brazil," said Dror Bashan, Protalix's Presi
10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
DEF 14A - Protalix BioTherapeutics, Inc. (0001006281) (Filer)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
SC 13G/A - Protalix BioTherapeutics, Inc. (0001006281) (Subject)
Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur
Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel, Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the Company's Board of Directors has appointed Eliot Richard Forster, Ph.D. to serve on the Board of Directors as its Chairman, effective as of September 14, 2023. In
CARMIEL, Israel, June 30, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), announced today that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi, Ph.D. to serve on the Company's Board of Directors. In addition to Dr. Ben Zvi's appointment as an independent director, he was also appointed to serve on the Company's Audit Committee and Compensation Committee. "We are excited to have Muli join our Board of Directors," commented Zeev Bronfeld, Chairman of Protalix's Board of Directors. "He brings extensive financial and economic knowle